A Shatavari (Asparagus racemosus) extract marketed by Waleria Healthtech Private Limited as aspurūs was associated with improvements in self-reported menopause symptoms in a randomized, double-blind, placebo-controlled study involving 70 women between the ages of 40 and 65. The findings were published in Cureus – Journal of Medical Sciences.
 
The women’s health market has grown substantially, driven largely by an awareness of menopause symptoms, reported Waleria, and as a result there’s been a surge in demand for dietary supplements targeting menopausal support. Companies are increasing research and development efforts surrounding women’s health products.
 
Aspurūs is a full-spectrum Shatavari root extract standardized to contain no less than 5% shatavarins, which are steroidal saponins unique to the plant, by high-performance thin-layer chromatography (HPTLC).
 
Study Details
 
In the present study, the 70 pre- and postmenopausal female participants were administered either a placebo or aspurūs for 8 weeks. At baseline, each of htem were experiencing symptoms like hot flashes, night sweats, anxiety, fatigue, and mood swings. The primary outcome measure was the total score of Utian Quality of Life (UQoL) on days 30 and 60.
 
The treatment group experienced reductions in the most commonly-experienced symptoms (hot flashes, night sweats, anxiety, fatigue, and insomnia) compared to those in the placebo group. UQoL improvements were also significantly greater in the treatment group, indicating that supplementation improved overall well-being. Highlights included an 85% reduction in hot flashes by week 4; a 90% reduction in night sweats in 8 weeks, and a 60% reduction in reported sleeplessness compared to placebo.
 
“Our study shows the potential of aspurūs in providing relief from major menopausal symptoms without the accompanying side effects often associated with conventional therapies,” said Komal Baldwa, founder of Waleria. “This offers hope for women seeking effective and safe alternatives during this transformative phase of life. Additionally, it gives manufacturers an opportunity to formulate with a clinically studied lower dose ingredient efficacious in reducing major menopausal symptoms.”
 
There were no significant adverse events reported by the treatment group, indicating that the ingredient was well-tolerated at the efficacious dose of 500 mg.
 
“The findings demonstrate the compelling evidence of the efficacy of aspurūs in supporting menopausal symptoms and enhancing overall quality of life,” said Danielle Greenberg, research consultant at Waleria. “The significant reductions in hot flashes and night sweats coupled with the notable improvements in Utian Quality of Life scores show the potential of aspurūs to offer meaningful relief for women experiencing menopausal transition.”